Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 11;4(4):100497.
doi: 10.1016/j.jtocrr.2023.100497. eCollection 2023 Apr.

Biopsy Method and Needle Size on Success of Next-Generation Sequencing in NSCLC: A Brief Report

Raymond Diep  1 , Madeline MacDonald  2 , Ryan Cooper  3 , Anna Grzegorczyk  4 , Rastko Rakocevic  4 , Ching-Fei Chang  4 , Angeline Uy  5 , Nicholas Cowgill  5 , Jorge J Nieva  2
Affiliations

Biopsy Method and Needle Size on Success of Next-Generation Sequencing in NSCLC: A Brief Report

Raymond Diep et al. JTO Clin Res Rep. .

Abstract

Introduction: Next-generation sequencing (NGS) is essential to the care of patients with NSCLC. Nevertheless, NGS is dependent on adequate material from biopsy. We evaluated the impact of biopsy method and needle gauge necessary for optimizing success in tissue NGS.

Methods: A total of 1660 formalin-fixed, paraffin-embedded samples were submitted to Caris Life Sciences from 2007 to 2022 for tumor profiling. The results of NGS assays were linked with retrospective biopsy data for patients with lung cancer treated at USC/Norris Cancer Center to create a database with the following parameters: demographics, biopsy method, tumor location (lung mass versus lymph node versus metastasis), needle gauge, number of needle passes, complications, tumor volume, DNA content, and status of NGS. Fisher's exact test and analysis of variance were performed to determine the impact of biopsy method and needle gauge (G).

Results: In total, 77 computed tomography (CT)-guided transthoracic core needle (CT-TTCN) biopsies, 74 endobronchial ultrasound (EBUS)-guided transbronchial needle aspirations (TBNAs), 27 bronchial forceps biopsies, and 107 surgical resections were included. Furthermore, 41 of 77 CT-TTCN biopsies (53.2%), 43 of 74 EBUS-TBNAs (58.1%), 22 of 27 bronchial forceps biopsies (81.5%), and 105 of 107 surgical resections (98.1%) underwent successful NGS assays. The probability of successful NGS completion for lung cancers was highest in surgical resections and bronchial forceps biopsies. Needle-based biopsies were more successful when a needle larger than 20G was used. Complication rates were higher for CT-TTCN biopsies compared with EBUS-TBNA (p < 0.0001). Overall, the DNA yield was significantly higher in EBUS-TBNA compared with CT-TTCN biopsies in primary lung sites (p = 0.0002). EBUS-TBNA was found to have higher success rates in NGS compared with CT-TTCN for both primary lung lesions (p = 0.023) and lymph node targets (p = 0.035).

Conclusions: The less invasive EBUS-TBNAs had higher success rates in NGS than CT-TTCN biopsies and resulted in higher DNA concentrations. In CT-TTCN biopsies, use of 20G or smaller needles is associated with a higher risk of obtaining an inadequate specimen regardless of the number of passes taken. Surgical and bronchial forceps biopsies had highest success in achieving NGS.

Keywords: Biopsy method; Fine-needle aspiration; Needle gauge; Next-generation sequencing (NGS); Non–small cell lung cancer (NSCLC); Transthoracic core needle biopsy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) Number of successful NGS and failed NGS cases in different CT-TTCN biopsy gauge sizes (∗∗∗∗p < 0.0001). (B) DNA yield between biopsy method/location (∗∗∗p = 0.0002). CT-TTCN, computed tomography–guided transthoracic core needle; EBUS-TBNA, endobronchial ultrasound–guided transbronchial needle aspiration; NGS, next-generation sequencing.
See this image and copyright information in PMC

References

    1. Ettinger D.S., Aisner D.L., Wood D.E., et al. NCCN guidelines insights: non-small cell lung cancer, version 5.2018. J Natl Compr Canc Netw. 2018;16:807–821. - PubMed
    1. Robert N.J., Espirito J.L., Chen L., et al. Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in the US Oncology Network. Lung Cancer. 2022;166:197–204. - PubMed
    1. Debora S., Bruno L.M.H., Li X., Su E.W., Zhu Y.E., Patel M. Racial disparities in biomarker testing and clinical trial enrollment in non-small cell lung cancer (NSCLC) J Clin Oncol. 2021;39(suppl 15)
    1. Chen M., Zhao H. Next-generation sequencing in liquid biopsy: cancer screening and early detection. Hum Genomics. 2019;13:34. - PMC - PubMed
    1. Dupain C., Masliah-Planchon J., Gu C., et al. Fine-needle aspiration as an alternative to core needle biopsy for tumour molecular profiling in precision oncology: prospective comparative study of next-generation sequencing in cancer patients included in the SHIVA02 trial. Mol Oncol. 2021;15:104–115. - PMC - PubMed

LinkOut - more resources